Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model

B. J. Kwon, G. M. Seon, M. H. Lee, M. A. Koo, M. S. Kim, D. Kim, J. J. Han, D. Kim, J. Kim, Jong Chul Park

Research output: Contribution to journalArticle

Abstract

Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in bone resorption that is not matched by sufficient bone formation. The most common complications of postmenopausal osteoporosis are bone-related defects and fractures. Fracture healing is a multifactorial bone regeneration process, influenced by both biological and mechanical factors related to age, osteoporosis and stability of the osteosynthesis. During the treatment of bone defects in osteoporotic conditions, imbalanced bone remodeling is the leading cause for implant failure. To overcome these problems, ethyl-2,5-dihydroxybenzoate (E-2,5-DHB), a drug that promotes bone formation and inhibits bone resorption, was used. E-2,5-DHB-incorporating titanium (Ti) implants using poly(lactic-co-glycolic acid) (PLGA) coating for local delivery of E-2,5-DHB were developed and the effects on bone healing of femoral defects were evaluated in an osteoporotic model. The release of E-2,5-DHB resulted in decreased bone resorption and increased bone formation around the implant. Thus, it was confirmed that, in the osteoporotic model, bone healing was increased and implant fixation was enhanced. These results suggested that E-2,5-DHB-coated Ti implants have great potential as an ultimate local drug delivery system for bone tissue scaffolds.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalEuropean Cells and Materials
Volume35
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Bone Regeneration
Bone
Animals
Animal Models
Bone and Bones
Bone Resorption
Osteogenesis
Titanium
Osteoporosis
Tissue Scaffolds
Postmenopausal Osteoporosis
Fracture Healing
Bone Remodeling
Biological Factors
Drug Delivery Systems
Thigh
2,5-dihydroxybenzoic acid
Defects
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biochemistry
  • Biomaterials
  • Biomedical Engineering
  • Cell Biology

Cite this

Kwon, B. J. ; Seon, G. M. ; Lee, M. H. ; Koo, M. A. ; Kim, M. S. ; Kim, D. ; Han, J. J. ; Kim, D. ; Kim, J. ; Park, Jong Chul. / Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model. In: European Cells and Materials. 2018 ; Vol. 35. pp. 1-12.
@article{b3aff7d4338d489799cd6cdee7acf528,
title = "Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model",
abstract = "Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in bone resorption that is not matched by sufficient bone formation. The most common complications of postmenopausal osteoporosis are bone-related defects and fractures. Fracture healing is a multifactorial bone regeneration process, influenced by both biological and mechanical factors related to age, osteoporosis and stability of the osteosynthesis. During the treatment of bone defects in osteoporotic conditions, imbalanced bone remodeling is the leading cause for implant failure. To overcome these problems, ethyl-2,5-dihydroxybenzoate (E-2,5-DHB), a drug that promotes bone formation and inhibits bone resorption, was used. E-2,5-DHB-incorporating titanium (Ti) implants using poly(lactic-co-glycolic acid) (PLGA) coating for local delivery of E-2,5-DHB were developed and the effects on bone healing of femoral defects were evaluated in an osteoporotic model. The release of E-2,5-DHB resulted in decreased bone resorption and increased bone formation around the implant. Thus, it was confirmed that, in the osteoporotic model, bone healing was increased and implant fixation was enhanced. These results suggested that E-2,5-DHB-coated Ti implants have great potential as an ultimate local drug delivery system for bone tissue scaffolds.",
author = "Kwon, {B. J.} and Seon, {G. M.} and Lee, {M. H.} and Koo, {M. A.} and Kim, {M. S.} and D. Kim and Han, {J. J.} and D. Kim and J. Kim and Park, {Jong Chul}",
year = "2018",
month = "1",
day = "1",
doi = "10.22203/eCM.v035a01",
language = "English",
volume = "35",
pages = "1--12",
journal = "European Cells and Materials",
issn = "1473-2262",
publisher = "Swiss Society for Biomaterials",

}

Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model. / Kwon, B. J.; Seon, G. M.; Lee, M. H.; Koo, M. A.; Kim, M. S.; Kim, D.; Han, J. J.; Kim, D.; Kim, J.; Park, Jong Chul.

In: European Cells and Materials, Vol. 35, 01.01.2018, p. 1-12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Locally delivered ethyl-2,5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model

AU - Kwon, B. J.

AU - Seon, G. M.

AU - Lee, M. H.

AU - Koo, M. A.

AU - Kim, M. S.

AU - Kim, D.

AU - Han, J. J.

AU - Kim, D.

AU - Kim, J.

AU - Park, Jong Chul

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in bone resorption that is not matched by sufficient bone formation. The most common complications of postmenopausal osteoporosis are bone-related defects and fractures. Fracture healing is a multifactorial bone regeneration process, influenced by both biological and mechanical factors related to age, osteoporosis and stability of the osteosynthesis. During the treatment of bone defects in osteoporotic conditions, imbalanced bone remodeling is the leading cause for implant failure. To overcome these problems, ethyl-2,5-dihydroxybenzoate (E-2,5-DHB), a drug that promotes bone formation and inhibits bone resorption, was used. E-2,5-DHB-incorporating titanium (Ti) implants using poly(lactic-co-glycolic acid) (PLGA) coating for local delivery of E-2,5-DHB were developed and the effects on bone healing of femoral defects were evaluated in an osteoporotic model. The release of E-2,5-DHB resulted in decreased bone resorption and increased bone formation around the implant. Thus, it was confirmed that, in the osteoporotic model, bone healing was increased and implant fixation was enhanced. These results suggested that E-2,5-DHB-coated Ti implants have great potential as an ultimate local drug delivery system for bone tissue scaffolds.

AB - Osteoporosis is a disease characterized by low bone mass, most commonly caused by an increase in bone resorption that is not matched by sufficient bone formation. The most common complications of postmenopausal osteoporosis are bone-related defects and fractures. Fracture healing is a multifactorial bone regeneration process, influenced by both biological and mechanical factors related to age, osteoporosis and stability of the osteosynthesis. During the treatment of bone defects in osteoporotic conditions, imbalanced bone remodeling is the leading cause for implant failure. To overcome these problems, ethyl-2,5-dihydroxybenzoate (E-2,5-DHB), a drug that promotes bone formation and inhibits bone resorption, was used. E-2,5-DHB-incorporating titanium (Ti) implants using poly(lactic-co-glycolic acid) (PLGA) coating for local delivery of E-2,5-DHB were developed and the effects on bone healing of femoral defects were evaluated in an osteoporotic model. The release of E-2,5-DHB resulted in decreased bone resorption and increased bone formation around the implant. Thus, it was confirmed that, in the osteoporotic model, bone healing was increased and implant fixation was enhanced. These results suggested that E-2,5-DHB-coated Ti implants have great potential as an ultimate local drug delivery system for bone tissue scaffolds.

UR - http://www.scopus.com/inward/record.url?scp=85055591207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055591207&partnerID=8YFLogxK

U2 - 10.22203/eCM.v035a01

DO - 10.22203/eCM.v035a01

M3 - Article

C2 - 29327779

AN - SCOPUS:85055591207

VL - 35

SP - 1

EP - 12

JO - European Cells and Materials

JF - European Cells and Materials

SN - 1473-2262

ER -